NewcelX adds Jeremy Shefner to advisory board

NewcelX Ltd. (NASDAQ: NCEL) announced the appointment of Jeremy Shefner, MD, PhD, to its Scientific Advisory Board. The biotechnology company develops cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.

Shefner serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona. He specializes in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders, and co-founded the Northeast ALS Clinical Trials Consortium. He has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures.

In his advisory role, Shefner will provide strategic guidance on NewcelX's ALS programs, including the clinical development of AstroRx, and support the integration of neuromuscular and neurodegenerative disease expertise into the company's platform.

"His leadership in ALS research and trial methodology strengthens our ability to bring advanced therapies to patients living with this devastating disease," said Ronen Twito, Executive Chairman and CEO of NewcelX, according to a company statement.

Shefner commented on the appointment: "I believe the Company's integrated approach—combining cell therapy and neuroscience—has significant potential to address ALS and other neurodegenerative diseases."

NewcelX is headquartered in Zurich, Switzerland, with research and development operations in Israel. The company's platform combines stem-cell technologies with neuroscience expertise to target conditions including ALS and Type 1 Diabetes.

You May Also Be Interested In

• Palisade Bio adds two industry veterans to board of directors
• Enliven Therapeutics reports phase 1 trial results for leukemia drug
• NextTrip acquires controlling stake in TikTok partner agency YADA